Development of a nomogram for predicting high-grade prostate cancer on biopsy: The significance of serum testosterone levels

Anticancer Research

Volumn 28, Issue 4 C, 2008, Pages 2487-2492

  Ide, Hisamitsu ^a   Yasuda, Mitsuko ^a   Nishio, Kojiro ^a   Saito, Keisuke ^a   Isotani, Shuji ^a   Kamiyama, Yutaka ^a   Muto, Satoru ^a   Horie, Shigeo ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Nomogram; Prostate biopsy; Prostate cancer; Prostate specific antigen; Testosterone

Indexed keywords

BIOLOGICAL MARKER; FOLLITROPIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGE; AGED; ANTIGEN DETECTION; ARTICLE; BLOOD CHEMISTRY; CANCER GRADING; CONTROLLED STUDY; EXTERNAL VALIDITY; FOLLITROPIN BLOOD LEVEL; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; ORGAN SIZE; PATIENT REFERRAL; PREDICTION; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROSTATE; PROSTATE BIOPSY; PROSTATE CANCER; SEX HORMONE DETERMINATION; STATISTICAL SIGNIFICANCE; TESTOSTERONE BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; DATA INTERPRETATION, STATISTICAL; FOLLICLE STIMULATING HORMONE; HUMANS; MALE; MIDDLE AGED; NOMOGRAMS; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 48849111874     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Jemal A, Ward E, Hao Y and Thun M: Trends in the leading causes of death in the United States, 1970-2002. JAMA 294: 1255-1259, 2005.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007.
3. Kamo K and Sobue T: Cancer statistics digest. Mortality trend of prostate, breast, uterus, ovary, bladder and "kidney and other urinary tract" cancer in Japan by birth cohort. Jpn J Clin Oncol 34: 561-563, 2004.
4. Beaulac JA, Fry RN and Onysko J: Lifetime and recent prostate-specific antigen (PSA) screening of men for prostate cancer in Canada. Can J Public Health 97: 171-176, 2006.
5. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ and Coltman CA Jr: The influence of finasteride on the development of prostate cancer. N Engl J Med 349: 215-224, 2003.
6. Nam RK, Toi A, Klotz LH, Trachtenberg J, Jewett MA, Loblaw A, Pond GR, Emami M, Sugar L, Sweet J and Narod SA: Nomogram prediction for prostate cancer and aggressive prostate cancer at time of biopsy: utilizing all risk factors and tumor markers for prostate cancer. Can J Urol 13(Suppl 2): 2-10, 2006.
7. Morgentaler A: Testosterone and prostate cancer: a historical perspective on a modern myth. Eur Urol 50: 935-939, 2006.
8. Yamamoto S, Yonese J, Kawakami S, Ohkubo Y, Tatokoro M, Komai Y, Takeshita H, Ishikawa Y and Fukui I: Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy. Eur Urol 52: 696-701, 2007.
9. Morgentaler A, Bruning CO III and DeWolf WC: Occult prostate cancer in men with low serum testosterone levels. JAMA 276: 1904-1906, 1996.
10. Isom-Batz G, Bianco FJ Jr, Kattan MW, Mulhall JP, Lilja H and Eastham JA: Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol 173: 1935-1937, 2005.
11. Massengill JC, Sun L, Moul JW, Wu H, McLeod DG, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D and Donahue T: Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 169: 1670-1675, 2003.
12. Yano M, Imamoto T, Suzuki H, Fukasawa S, Kojima S, Komiya A, Naya Y and Ichikawa T: The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening. Eur Urol 51: 375-380, 2007.
13. Eastham JA, May R, Robertson JL, Sartor O and Kattan MW: Development of a nomogram that predicts the probability of a positive prostate biopsy in men with an abnormal digital rectal examination and a prostate-specific antigen between O and 4 ng/mL. Urology 54: 709-713, 1999.
14. Yanke BV, Carver BS, Bianco FJ Jr, Simoneaux WJ, Venable DD, Powell IJ and Eastham JA: African-American race is a predictor of prostate cancer detection: incorporation into a prebiopsy nomogram. BJU Int 98: 783-787, 2006.
15. Karakiewicz PI, Benayoun S, Kattan MW, Perrotte P, Valiquette L, Scardino PT, Cagiannos I, Heinzer H, Tanguay S, Aprikian AG, Huland H and Graefen M: Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. J Urol 173: 1930-1934, 2005.
16. Suzuki H, Komiya A, Kamiya N, Imamoto T, Kawamura K, Miura J, Suzuki N, Nakatsu H, Hata A and Ichikawa T: Development of a nomogram to predict probability of positive initial prostate biopsy among Japanese patients. Urology 67: 131-136, 2006.
17. Singh H, Canto EI, Shariat SF, Kadmon D, Miles BJ, Wheeler TM and Slawin KM: Improved detection of clinically significant, curable prostate cancer with systematic 12-core biopsy. J Urol 171: 1089-1092, 2004.
18. Emiliozzi P, Scarpone P, DePaula F, Pizzo M, Federico G, Pansadoro A, Martini M and Pansadoro V: The incidence of prostate cancer in men with prostate-specific antigen greater than 4.0 ng/ml: a randomized study of 6 versus 12 core transperineal prostate biopsy. J Urol 171: 197-199, 2004.
19. Chun FK, Karakiewicz PI, Huland H and Graefen M: Role of nomograms for prostate cancer in 2007. World J Urol 25: 131-142, 2007.
20. Djavan B, Zlotta A, Kratzik C, Remzi M, Seitz C, Schulman CC and Marberger M: PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL. Urology 54: 517-522, 1999.
21. Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, Feng Z, Parnes HL and Coltman CA Jr: Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 98: 529-534, 2006.
22. Fall K, Garmo H, Andren O, Bill-Axelson A, Adolfsson J, Adami HO, Johansson JE and Holmberg L: Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst 99: 526-532, 2007.
23. Waltregny D, Leav I, Signoretti S, Soung P, Lin D, Merk F, Adams JY, Bhattacharya N, Cirenei N and Loda M: Androgen-driven prostate epithelial cell proliferation and differentiation in vivo involve the regulation of p27. Mol Endocrinol 75: 765-782, 2001.
24. Nishiyama T, Ikarashi T, Hashimoto Y, Suzuki K and Takahashi K: Association between the dihydrotestosterone level in the prostate and prostate cancer aggressiveness using the Gleason score. J Urol 176: 1387-1391, 2006.
25. Phillips TH and Thompson IM: Digital rectal examination and carcinoma of the prostate. Urol Clin North Am 18: 459-465, 1991.
26. Curran V, Solberg S, Mathews M, Church J, Buehler S, Wells J and Lopez T: Prostate cancer screening attitudes and continuing education needs of primary care physicians. J Cancer Educ 20: 162-166, 2005.
27. Garzotto M, Hudson RG, Peters L, Hsieh YC, Barrera E, Mori M, Beer TM and Klein T: Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate-specific antigen levels < or =10 ng/mL. Cancer 98: 1417-1422, 2003.